Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board

Study: surgery prior to drug treatment not beneficial in metastasized breast cancer

July 06, 2017
Vol.40 No.06

Three-week radiation therapy treatment given post-mastectomy is safe and effective

June 01, 2017
Vol.40 No.05

Phase III abemaciclib study shows PFS improvement at interim analysis

May 01, 2017
Vol.40 No.04

Phase III MONARCH 2 study of abemaciclib meets primary endpoint of PFS

March 30, 2017
Vol.40 No.03

Blood Test That Detects Changes in Tumor DNA Predicts Survival in Advanced Disease

February 28, 2017
Vol.40 No.02

MammaPrint Substantially Impacts How Breast Cancer in Germany is Treated

January 25, 2017
Vol.40 No.01

Lilly Presents Phase II Data on Abemaciclib in Early Breast Cancer

December 22, 2016
Vol.39 No.11

Novartis’s LEE011 + Letrozole Shows Superior PFS as First-Line Treatment for HR+/HER2- Advanced Breast Cancer

October 20, 2016
Vol.39 No.09

Abemaciclib Phase III Trial Continues After Interim Efficacy Criteria Not Met

September 22, 2016
Vol.39 No.08

Phase III Trial Rules Out Inferiority of Trastuzumab Biosimilar ABP 980

August 04, 2016
Vol.39 No.07

Posts navigation

Previous1…303132Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Michael Bishop, Nobel-winning cancer researcher, dies at 90
  • Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • FDA issues warning letter to ImmunityBio over misleading claims about cancer drug

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account